WO2007108615A1 - Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof - Google Patents

Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof Download PDF

Info

Publication number
WO2007108615A1
WO2007108615A1 PCT/KR2007/001307 KR2007001307W WO2007108615A1 WO 2007108615 A1 WO2007108615 A1 WO 2007108615A1 KR 2007001307 W KR2007001307 W KR 2007001307W WO 2007108615 A1 WO2007108615 A1 WO 2007108615A1
Authority
WO
WIPO (PCT)
Prior art keywords
clopidogrel
naphthalenedisulfonate
organic solvent
mixture
formula
Prior art date
Application number
PCT/KR2007/001307
Other languages
French (fr)
Inventor
Kwee Hyun Suh
Sang Min Yun
Eun Sook Kim
Gwan Sun Lee
Original Assignee
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm. Co., Ltd. filed Critical Hanmi Pharm. Co., Ltd.
Priority to NZ572170A priority Critical patent/NZ572170A/en
Priority to US12/293,959 priority patent/US7612207B2/en
Priority to AU2007227930A priority patent/AU2007227930A1/en
Priority to EP07715692A priority patent/EP2001889A4/en
Publication of WO2007108615A1 publication Critical patent/WO2007108615A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/06—Diaphragms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/54—Control of apparatus or devices for radiation diagnosis
    • A61B6/542—Control of apparatus or devices for radiation diagnosis involving control of exposure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/56—Details of data transmission or power supply, e.g. use of slip rings
    • A61B6/566—Details of data transmission or power supply, e.g. use of slip rings involving communication between diagnostic systems
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B42/00—Obtaining records using waves other than optical waves; Visualisation of such records by using optical means
    • G03B42/02—Obtaining records using waves other than optical waves; Visualisation of such records by using optical means using X-rays

Definitions

  • water-miscible solvents methanol, ethanol, isopropanol, acetone, methylethylketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, acetonitrile, tetrahydrofuran and 1,4-dioxane are preferred, and methanol, ethanol, isopropanol and acetone are more preferred.
  • 1,5-naphthalenedisulfonate monohydrate (95 %, 3.7 mmol) were suspended in a mixture of 20 mi of isopropanol and 10 mi of distilled water, and the suspension was homogenized at 70 °C .
  • the resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then at 5 ° C for 2 hours.
  • the resulting precipitates were filtered under a reduced pressure, washed with 3 mfl of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 0 C for 4 hours, to obtain 3.2 g of the title compound (yield: 91 %) as an white powder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to a method for preparing clopidogrel 1,5-naphthalenedisulfonate or a hydrate thereof, which comprises reacting a clopidogrel-acid addition salt with disodium 1,5-naphthalenedisulfonate or its hydrate in water, or a mixture of water and an organic solvent. High quality clopidogrel 1,5-naphthalenedisulfonate can be prepared by the inventive method by way of using non-corrosive disodium 1,5-naphthalenedisulfonate.

Description

METHOD FOR PREPARING CLOPIDOGREL 1,5- NAPHTHALENEDISULFONATE OR HYDRATE THEREOF
FIELD OF THE INVENTION
The present invention relates to a method for preparing clopidogrel 1,5- naphthalenedisulfonate or hydrate thereof.
BACKGROUND OF THE INVENTION
Clopidogrel (methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2- a]pyridine-5(4H)-acetate) of formula (IV), which has inhibiting activity against platelet agglutination, is a useful vascular diseases therapeutic for treating peripheral artery diseases such as stroke, thrombosis and embolism, as well as ischemic heart diseases such as myocardial infarction and angina pectoris:
Figure imgf000002_0001
(IV)
Clopidogrel, an optically active dextrorotatory compound, however, is an oil phase which is unstable under moist and high temperature conditions and is difficult to be purified to the level of required for pharmaceutical use.
Accordingly, acid addition salts of clopidogrel, which are stable solid and easy to purify, have been developed. Clopidogrel 1,5-naρhthalenedisulfonate (napadisilate (INN)), one of the most stable acid addition salts, has been disclosed in International Publication No. WO 2005/097804, wherein clopidogrel 1,5- naphthalenedisulfonate is prepared by reacting the free base form of clopidogrel with 1,5-naphthalenedisulfonic acid.
However, 1,5-naphthalenedisulfonic acid used in the above method (Armstrong acid) is a strong acid having a pKai value of -3.37 and a pKa2θf -2.64, and is not suitable for use in the preparation of high quality clopidogrel 1,5- naphthalenedisulfonate due to its corrosivness, handling in a bulk production process and tendency to color the product red. Accordingly, there has been a need for an improved method of preparing clopidogrel 1,5-naphthalenedisulfonate. The present inventors have found that clopidogrel 1,5- naphthalenedisulfonate can be beneficially prepared by reacting a clopidogrel acid addition salt with a 1,5-naphthalenedisulfonate, which is not acidic nor corrosive.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a new method of preparing clopidogrel 1,5-naphthalenedisulfonate, which can ameliorate the problems associated with the conventional methods.
In accordance with an aspect of the present invention, there is provided a method for preparing clopidogrel 1,5-naphthalenedisulfonate of formula (I) or a hydrate thereof, which comprises:
Figure imgf000003_0001
(I) reacting a clopidogrel-acid addition salt of formula (II)
Figure imgf000003_0002
(H) with disodium 1,5-naphthalenedisulfonate of formula (III) or its hydrate
Figure imgf000004_0001
(III) in water, or a mixture of water and an organic solvent, wherein HX is an acid capable of reacting with clopidogrel to form an acid addition salt excluding naphthalenedisulfonate.
DETAILED DESCRIPTION OF THE INVENTION
The method of the present invention is characterized in that disodium 1,5- naphthalenedisulfonate, which is non-corrosive and non-acidic is used as a starting material, instead of 1,5-naphthalenedisulfonic acid.
The inventive method of preparing clopidogrel 1,5 -naphthalenedisulfonate of formula (I) or a hydrate thereof may be carried out by adding the clopidogrel- acid addition salt of formula (II) and disodium 1,5-naphthalenedisulfonate of formula (III) to water or a water-organic solvent mixture to obtain a solution or a suspension; stirring the solution or the suspension at a temperature ranging from 0 °C to the boiling point of the solvent used, preferably from room temperature to the boiling point of the solvent used.
Examples of the organic solvent which may be used in the present invention include water-miscible solvents selected from the group consisting of C1-3 alcohols such as methanol, ethanol, isopropanol; ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone; alkyl acetates such as methyl acetate, ethyl acetate, isopropyl acetate; acetonitrile; tetrahydrofuran; and 1,4-dioxane; as well as water-immiscible solvents selected from the group consisting of C6 or higher alkanes such as n-hexane, n-heptane, n-octane, isooctane; dialkyl ethers such as diethyl ether, diisopropyl ether; chloroalkanes such as dichloromethane, 1,2-dichloroethane, chloroform; aromatic solvents such as benzene and toluene; and a mixture thereof. Among those, water-miscible solvents, methanol, ethanol, isopropanol, acetone, methylethylketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, acetonitrile, tetrahydrofuran and 1,4-dioxane are preferred, and methanol, ethanol, isopropanol and acetone are more preferred.
Although the water-organic solvent mixture may have any organic solvent content, the preferred amount of the organic solvent is less than 95 % by volume based on the mixture, which helps the removal of the incidental salt.
Disodium 1,5-naphthalenedisulfonate of formula (III) or its hydrate may be employed in an amount ranging from 0.45 to 0.7 mole per mole of clopidogrel acid addition salt of formula (II). The clopidogrel acid addition salt of formula (II) may be any of those disclosed by European Patent No. 0281459 or International Publication No. WO 2004/074215. Representative examples of the clopidogrel acid addition salt include inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, hydrogen sulfate, phosphate, perchlorate and nitrate; sulfonates such as methanesulfonate, ethanesulfonate, 1,2-ethanedisulfonate, benzenesulfonate, p- toluenesulfonate, camphorsulfonate, laurylsulfonate, 2-naphthalenesulfonate; alkyl sulfates such as methyl sulfate and ethyl sulfate; organic acid salts such as acetate, oxalate, trifluoroacetate, propionate, benzoate, citrate, tartarate, succinate, malonate, lactate, malate, maleate and fumarate. Preferred among the above are hydrochloride, hydrobromide, hydrogen sulfate, camphorsulfonate and benzenesulfonate of clopidogrel.
The present invention will be described in further detail with reference to Examples. However, it should be understood that the present invention is not restricted by the specific Examples.
Preparation of clopidogrel 1,5-naphthalenedisulfonate monohydrate
Example 1
1.0 g of clopidogrel hydrochloride (2.8 mmol) was dissolved in a mixture of 10 m& of methanol and 10 ml of distilled water, and 515 mg of disodium 1,5- naphthalenedisulfonate monohydrate (95 %, 1.4 mmol) was added thereto. The resulting solution was stirred at room temperature for 15 hours, and then at 5 "C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 1 ml of a mixture of methanol and distilled water (1/2, v/v), and dried at 50 °C for 4 hours, to obtain 1.1 mg of the title compound (yield: 85 %) as a white powder.
M.p.: 221-224 °C (reported value: 223-225 TJ); Water contents (Karl-Fisher titrator): 1.9 %; (theoretical value: 1.90 %) Purity (HPLC): 98.7 % (purity of standard product: 99.3 %)
Example 2
3.0 g of clopidogrel hydrochloride (8.4 mmol) and 1.54 g of disodium 1,5- naphthalenedisulfonate monohydrate (95 %, 4.2 mmol) were suspended in a mixture of 20 mi of isopropanol and 10 mi of distilled water and the suspension was homogenized at 70 "C . The resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 3 ml of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 0C for 4 hours, to obtain 3.5 g of the title compound (yield: 88 %) as a white powder.
M.p.: 220-224 "C (reported value: 223-225 "C );
Water contents (Karl-Fisher titrator): 1.80 %; (theoretical value: 1.90 %)
Example 3
3.0 g of clopidogrel hydrobromide (7.4 mmol) and 1.37 g of disodium
1,5-naphthalenedisulfonate monohydrate (95 %, 3.7 mmol) were suspended in a mixture of 20 mi of isopropanol and 10 mi of distilled water, and the suspension was homogenized at 70 °C . The resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 3 mfl of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 0C for 4 hours, to obtain 3.2 g of the title compound (yield: 91 %) as an white powder.
M.p.: 221-224 °C (reported value: 223-225 1C);
Water contents (Karl-Fisher titrator): 2.0 %; (theoretical value: 1.90 %)
Example 4
5.0 g of clopidogrel besylate (10.4 mmol) and 1.92 g of disodium 1,5- naphthalenedisulfonate monohydrate (95 %, 5.2 mmol) were suspended in a mixture of 20 mi of methanol and 15 mi of distilled water and the suspension was homogenized at 60 °C . The resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 6 M of a mixture of methanol and distilled water (1/1, v/v), and dried at 50 0C for 4 hours, to obtain 4.6 g of the title compound (yield: 94 %) as a white powder.
M.p.: 220-224 0C (reported value: 223-225 °C);
Water contents (Karl-Fisher titrator): 1.75 %; (theoretical value: 1.90 %)
Example 5
5.0 g of clopidogrel besylate (10.4 mmol) and 1.92 g of disodium 1,5- naphthalenedisulfonate monohydrate (95 %, 5.2 mmol) were suspended in a mixture of 30 mi of isopropanol and 15 mi of distilled water and the suspension was homogenized at 70 0C . The resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 6 ml of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 °C for 4 hours, to obtain 4.2 g of the title compound (yield: 86 %) as a white powder.
M.p.: 220-224 °C (reported value: 223-225 0C); Water contents (Karl-Fisher titrator): 1.8 %; (theoretical value: 1.90 %)
Example 6
3.0 g of clopidogrel (+)-(lS)-camphor-10-sulfonate (5.4 mmol) and 998 fflg of disodium 1,5-naphthalenedisulfonate monohydrate (95 %, 2.7 mmol) were suspended in a mixture of 20 mi of isopropanol and 10 mi of distilled water and the suspension was homogenized at 70 °C . The resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 3 mi of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 °C for 4 hours, to obtain 2.4 g of the title compound (yield: 92 %) as a white powder.
M.p.: 220-223 °C (reported value: 223-225 0C); Water contents (Karl-Fisher titrator): 2.0 %; (theoretical value: 1.90 %)
Example 7
3.0 g of clopidogrel (-)-(lR)-camρhor-10-sulfonate (5.4 mmol) and 998 mg of disodium 1,5-naphthalenedisulfonate monohydrate (95 %, 2.7 mmol) were suspended in a mixture of 20 mi of isopropanol and 10 mi of distilled water and the suspension was homogenized at 70 "C . The resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 3 ml of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 "C for 4 hours, to obtain 2.3 g of the title compound (yield: 88 %) as an white powder. M.p.: 221-224 °C (reported value: 223-225 °C);
Water contents (Karl-Fisher titrator): 1.75 %; (theoretical value: 1.90 %)
Example 8
3.0 g of clopidogrel hydrogen sulfate (7.1 mmol) and 1.32 g of disodium 1,5-naphthalenedisulfonate monohydrate (95 %, 3.6 mmol) were suspended in a mixture of 20 mi of isopropanol and 10 ml of distilled water and the suspension was homogenized at 70 °C . The resulting precipitates were slowly cooled; and stirred at room temperature for 15 hours, and then at 5 "C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 6 m£ of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 "C for 4 hours, to obtain 3.2 g of the title compound (yield: 94 %) as a white powder.
M.p.: 220-223 °C (reported value: 223-225 °C);
Water contents (Karl-Fisher titrator): 1.7 %; (theoretical value: 1.90 %)
Example 9
1.0 g of clopidogrel hydrogen sulfate (2.4 mmol) and 439 mg of disodium 1,5-naphthalenedisulfonate monohydrate (95 %, 1.2 mmol) were suspended in a mixture of 5 mi of methanol and 10 ml of distilled water and the suspension was homogenized at 70 0C . The resulting solution was slowly cooled; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 6 ml of a mixture of isopropanol and distilled water (2/1, v/v), and dried at 50 0C for 4 hours, to obtain 3.2 g of the title compound (yield: 94 %) as a white powder.
M.p.: 220-223 °C (reported value: 223-225 °C);
Water contents (Karl-Fisher titrator): 1.7 %; (theoretical value: 1.90 %) Example 10
1.0 g of Clopidogrel hydrogen sulfate (2.4 mmol) and 439 mg of disodium 1,5-naphthalenedisulfonate monohydrate (95 %, 1.2 mmol) were dissolved in 10 mi of distilled water; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 3 mi of distilled water, and dried at 50 "C for 4 hours, to obtain 0.9 g of the title compound (yield: 84 %) as a white powder.
M.p.: 220-223 0C (reported value: 223-225 °C);
Water contents (Karl-Fisher titrator): 2.0 %; (theoretical value: 1.90 %)
Example 11
1.0 g of Clopidogrel hydrogen sulfate (2.4 mmol) and 439 mg of disodium 1,5-naphthalenedisulfonate monohydrate (95 %, 1.2 mmol) were suspended in a mixture of 7 mi of toluene and 10 mi of distilled water; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 3 mi of distilled water, and dried at 50 0C for 4 hours, to obtain 0.9 g of the title compound (yield: 84 %) as a white powder.
M.p.: 221-224 0C (reported value: 223-225 °C); Water contents (Karl-Fisher titrator): 1.9 %; (theoretical value: 1.90 %)
Example 12
1.0 g of Clopidogrel hydrogen sulfate (2.4 mmol) and 439 mg of disodium 1,5-naphthalenedisulfonate monohydrate (95 %, 1.2 mmol) were suspended in a mixture of 7 mi of diethyl ether and 10 mi of distilled water; and stirred at room temperature for 15 hours, and then at 5 °C for 2 hours. The resulting precipitates were filtered under a reduced pressure, washed with 3 ml of distilled water, and dried at 50 °C for 4 hours, to obtain 0.91 g of the title compound (yield: 85 %) as a white powder.
M.p.: 221-224 °C (reported value: 223-225 °C);
Water contents (Karl-Fisher titrator): 1.8 %; (theoretical value: 1.90 %)
As discussed above, the present invention provides an easy method for preparing clopidogrel 1,5-naphthalenedisulfonate or its hydrate on a large scale, in which disodium 1,5-naphthalenedisulfonate, a non-corrosive and non-coloring starting material is used without any of the problems encountered in the conventional method.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A method for preparing clopidogrel 1,5-naphthalenedisulfbnate of formula (I) or a hydrate thereof, which comprises:
Figure imgf000012_0001
(I) reacting a clopidogrel-acid addition salt of formula (II)
Figure imgf000012_0002
with disodium 1,5-naphthalenedisulfonate of formula (III) or its hydrate
Figure imgf000012_0003
in water, or a mixture of water and an organic solvent, wherein HX is an acid capable of reacting with clopidogrel to form an acid addition salt excluding naphthalenedisulf onate .
2. The method of claim 1, wherein the organic solvent is selected from the group consisting of Ci-3 alkyl alcohols, ketones, alkyl acetates, acetonitrile, tetrahydrofuran, 1,4-dioxane, C6 Or higher alkanes, dialkyl ethers, chloroalkanes and aromatic solvents.
3. The method of claim 2, wherein the organic solvent is selected from the group consisting of methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, acetonitrile, tetrahydrofuran and 1,4-dioxane.
4. The method of claim 3, wherein the organic solvent is selected from the group consisting of methanol, ethanol, isopropanol and acetone.
5. The method of claim 1, wherein the mixture of water and the organic solvent comprises the organic solvent in amount of less than 95% by volume based on the mixture.
6. The method of claim 1, wherein disodium 1,5-naphthalenedisulfonate of formula (III) or its hydrate is employed in an amount ranging from 0.45 to 0.7 equivalent based on the acid addition salt of formula (II). ,
7. The method of claim I5 wherein HX is an acid which forms an acid addition salt selected from the group consisting of inorganic acid salts, sulfonates, alkyl sulfates and organic acid salts.
8. The method of claim 7, wherein the acid addition salt is selected from the group consisting of hydrochloride, hydrobromide, hydrogen sulfate, benzene sulfonate and camphorsulfonate.
PCT/KR2007/001307 2006-03-22 2007-03-16 Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof WO2007108615A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
NZ572170A NZ572170A (en) 2006-03-22 2007-03-16 Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof
US12/293,959 US7612207B2 (en) 2006-03-22 2007-03-16 Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof
AU2007227930A AU2007227930A1 (en) 2006-03-22 2007-03-16 Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof
EP07715692A EP2001889A4 (en) 2006-03-22 2007-03-16 Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060026110A KR100945062B1 (en) 2006-03-22 2006-03-22 Method of preparing clopidogrel 1,5-naphthalenedisulfonate and hydrate thereof
KR10-2006-0026110 2006-03-22

Publications (1)

Publication Number Publication Date
WO2007108615A1 true WO2007108615A1 (en) 2007-09-27

Family

ID=38522620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/001307 WO2007108615A1 (en) 2006-03-22 2007-03-16 Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof

Country Status (7)

Country Link
US (1) US7612207B2 (en)
EP (1) EP2001889A4 (en)
KR (1) KR100945062B1 (en)
AU (1) AU2007227930A1 (en)
NZ (1) NZ572170A (en)
WO (1) WO2007108615A1 (en)
ZA (1) ZA200809005B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110015254A (en) * 2009-08-07 2011-02-15 한미홀딩스 주식회사 Prasugrel disulfonate salts and crystals thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080890A1 (en) * 2004-02-24 2005-09-01 Siegfried Generics International Ag Pharmacologically acceptable salts of clopidogrel
KR20050099445A (en) * 2004-04-09 2005-10-13 한미약품 주식회사 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparating same and pharmaceutical composition containing same
WO2005103059A1 (en) * 2004-04-20 2005-11-03 Sanofi-Aventis Clopidogrel salt and polymorphic forms thereof
US20050256152A1 (en) * 2003-02-13 2005-11-17 Karlheinz Doser Salt of a sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006143A (en) * 1974-04-09 1977-02-01 Merck & Co., Inc. Heterocyclic substituted pyrimidine compounds
US6902861B2 (en) * 2003-03-10 2005-06-07 Kodak Polychrome Graphics, Llc Infrared absorbing compounds and their use in photoimageable elements
CN1590387A (en) * 2003-08-29 2005-03-09 上海子能高科股份有限公司 Preparation method of mehailuolin -1,5- naphthaline disulfonate
CN1938319B (en) 2004-04-09 2010-05-12 韩美药品株式会社 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256152A1 (en) * 2003-02-13 2005-11-17 Karlheinz Doser Salt of a sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations
WO2005080890A1 (en) * 2004-02-24 2005-09-01 Siegfried Generics International Ag Pharmacologically acceptable salts of clopidogrel
KR20050099445A (en) * 2004-04-09 2005-10-13 한미약품 주식회사 Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparating same and pharmaceutical composition containing same
WO2005103059A1 (en) * 2004-04-20 2005-11-03 Sanofi-Aventis Clopidogrel salt and polymorphic forms thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2001889A4 *

Also Published As

Publication number Publication date
EP2001889A4 (en) 2009-04-01
ZA200809005B (en) 2010-01-27
AU2007227930A1 (en) 2007-09-27
EP2001889A1 (en) 2008-12-17
US7612207B2 (en) 2009-11-03
KR20070095646A (en) 2007-10-01
US20090036683A1 (en) 2009-02-05
NZ572170A (en) 2010-06-25
KR100945062B1 (en) 2010-03-05

Similar Documents

Publication Publication Date Title
US7482453B2 (en) Process for the manufacture of (+)-(S)-clopidogrel bisulfate form-1
US6180793B1 (en) Process for the preparation of a pharmacologically active substance
EA006198B1 (en) Process for preparing clopidogrel
JP2005522441A (en) Clopidogrel hydrochloride polymorph and use as antithrombin compound
EP0617037B1 (en) Enantioselective synthesis of thieno(2,3-b) thiopyran-7, 7-dioxide compounds
KR101050105B1 (en) (S) - (+) - clopidogrel bisulfate
WO2006042481A1 (en) Method of obtaining clopidogrel
US20080214821A1 (en) Method of Preparing Clopidogrel and Intermediates Used Therein
JP2002529462A (en) Racemization method
CN102850347A (en) Resolution method for pyrazole derivative or salt thereof
WO2012156384A1 (en) Novel crystalline salts of asenapine
US7612207B2 (en) Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof
US20070142637A1 (en) Process for the preparation of crystalline polymorph of a platelet aggregation inhibitor drug
WO2011083955A2 (en) Method for manufacturing crystalline form (i) of clopidogrel hydrogen sulphate
WO2008068569A2 (en) Processes for the preparation of clopidogrel hydrochloride
EP2107061A1 (en) Process for the preparation of optically enriched clopidogrel
KR101235117B1 (en) Process for the preparation of S-(+)-clopidogrel by optical resolution
KR100834967B1 (en) Process for the high yield production of clopidogrel by racemization of residual liquid
KR100742134B1 (en) Pharmaceutical composition comprising crystalline s-(+)-methyl-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate.camsylate
KR100563455B1 (en) Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparating same and pharmaceutical composition containing same
WO2009080469A1 (en) Process for the preparation of clopidogrel bisulphate form i
US20110263858A1 (en) Process for the preparation of clopidogrel hydrogen sulphate form i
EP2064217B1 (en) An improved process for the preparation of clopidogrel and its pharmaceutically acceptable salts
JP2007516166A (en) Preparation of amorphous form of platelet aggregation inhibitor
KR20090004269A (en) Polymorph form ii of racemic clopidogrel carboxylic acid monohydrate, and process for the preparation it

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07715692

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12293959

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007227930

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 572170

Country of ref document: NZ

Ref document number: 2007715692

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007227930

Country of ref document: AU

Date of ref document: 20070316

Kind code of ref document: A